Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$115.1MCash, Jun 2026
20moCash Runway (est.)
Follow ATTO by emailGet an email when ATTO pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ATTO, unsubscribe in one click. Privacy
📣 What ATTO Says Is Next
first half of 2027 · “IND-enabling activities are ongoing with Phase 1 initiation expected in the first half of 2027.”
Company press release, Sep 2, 2026 · SEC filing
first half of 2027 · “Global Phase 2 study in patients with high-itch AD is planned to initiate in the first half of 2027.”
Company press release, Sep 2, 2026 · SEC filing
fourth quarter of 2026 · “Complete Phase 1b data are expected in the fourth quarter of 2026.”
Company press release, Sep 2, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
ATTO reported $115.1M in cash and short-term investments (as of Jun 30, 2026) and used about $17.6M/quarter in operations, an estimated runway of 19.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:6 · Low
Cash runway 20 months +8
S-1 registration (Jul 2026) +8
Raised after last reported balance sheet (Aug 2026) -10
Recent financing filings on SEC EDGAR:
Aug 5, 2026 · Underwritten offering, $289M · 424B4
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ATTO and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.